



# Unravelling Cancer's Blueprint

Precision oncology advancing first-in-class therapeutics for patients with high-risk cancers.

# Disclaimer



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

For the purposes of this document, the "Presentation" shall mean and include this document, the slides that follow, the oral briefing provided by the Company and the proposed Acquisition (as defined below) in connection with the information herein, the question and answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with the Presentation or otherwise made available in connection with the Company and . This Presentation has been prepared by Roquefort Therapeutics plc (the "Company"), in connection with the proposed acquisition of the exclusive license rights to AO-252 by the Company ("Acquisition"), the proposed placing (the "Placing") of new ordinary shares in the capital of the Company (the "Placing Shares") and the application for the admission (the "Admission") of the entire issued and to be issued ordinary share capital of the Company to trading on AIM, a market operated by London Stock Exchange Group plc (respectively, "AIM" and the "London Stock Exchange"). This Presentation has been prepared for information only and solely for use by the Company at presentations to a limited number of parties. Recipients of the presentation who wish to acquire Placing Shares are reminded that any decision to subscribe may only be made solely on the basis of the information contained in the Company's final admission document to be published in connection with Admission, which may be different from the information contained in this Presentation. This Presentation is not an approved prospectus or other equivalent offering document under the securities laws of any jurisdiction.

Neither this Presentation nor any copy of it may be (a) taken or transmitted into the United States of America, Canada, Japan, the Republic of South Africa or any other jurisdiction (or their territories or possessions) in which it would be unlawful to do so (except Australia, subject to compliance with applicable Australian securities laws); or (b) distributed to any individual outside the United States of America, Canada, Japan or the Republic of South Africa who is a resident thereof or who is a resident of any other jurisdiction in which it would be unlawful to take or transmit this Presentation in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this Presentation in or to persons subject to other jurisdictions (including Australia) may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. By accepting delivery of this Presentation and by reading the information contained herein (including this notice), the recipient unconditionally agrees to be bound by the following limitations and obligations contained in this notice. Neither this Presentation, its contents, nor any part thereof have been approved (for the purposes of section 21 of the Financial Services and Markets Act 2000 ("FSMA")) or verified by an authorised person within the meaning of FSMA. Reliance on this Presentation for the purposes of engaging in any investment activity may expose an individual to a significant risk of losing all the assets invested. The information contained in this Presentation is being supplied to a very limited number of persons for information purposes only. This Presentation is not an offer to sell or invitation or solicitation of any offer to acquire securities of the Company, nor does it form a prospectus or part of any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) nor does it constitute an offer to the public in the United Kingdom (within the meaning of Regulation 7 of Public Offers and Admissions to Trading Regulations 2024/105 ("POATRs") and no offer will be made unless the offer is of a kind specified in Part 1 of Schedule 1 to the POATRs or a combination of two or more such kinds of offers, pursuant to Regulation 12 of the POATRs.. It shall not form the basis of, or be relied on in connection with, or act as invitation or inducement to enter into, any contract or commitment whatsoever. No offer of securities is being or will be made in circumstances which would require a prospectus or similar document to be approved. The Presentation is strictly confidential, is being supplied to you solely for your information and may not be distributed or re-distributed (including to the press) or passed to any other person, may not be copied in any form and may not be published, in whole or in part, for any purpose. Failure to comply with this restriction may, inter alia, constitute a violation of applicable securities laws. Certain information contained in the Presentation is non-public, proprietary and highly confidential. Accordingly, by accepting and using this document, you will be deemed to agree not to disclose any information contained in the Presentation except as may be required by law. The Presentation may contain unpublished price sensitive information with regard to the Company and/or its securities. Recipients of the Presentation should not deal or encourage any other any other person to deal in the securities of the Company whilst they remain in possession of such unpublished price sensitive information and until the transaction described in the Presentation is announced. Dealing in securities of the Company when in possession of unpublished price sensitive information could result in liability under the insider dealing restrictions set out in the Criminal Justice Act 1993 and the Market Abuse Regulations (EU) No 596/2014 (incorporated into UK law by virtue of the European Union (Withdrawal) Act 2018). This Presentation may contain information which is not generally available, but which, if available, would or would be likely to be regarded as relevant when deciding the terms on which transactions in the shares of the Company should be effected. Unreasonable behaviour based on such information could result in liability under the market abuse provisions of FSMA. This Presentation is directed at, and is only being made available to, persons in the United Kingdom who are qualified investors within the meaning of Article 2(e) of the Prospectus Regulation (Regulation 2017/1129) as applicable in the United Kingdom and as amended by the Prospectus (Amendment etc) (EU Exit) Regulations 2019 (SI2019/1234) and who are (a) persons who have professional experience in matters relating to investments and who fall within the category of person set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), being investment professionals or (b) persons to whom Article 49(2) of the Order applies, being high net worth companies, unincorporated associations, partnerships or trusts or their respective directors, officers or employees as described in Article 49 of the Order. Persons who do not fall within one of the categories of persons described above should not rely on this Presentation nor take any action upon it and should return it to the Company immediately. By accepting or electronically accessing this Presentation, the recipient represents, warrants and undertakes to the Company that they (a) are a person who falls within the above description of persons entitled to receive the Presentation, (b) will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (c) have read and agree to comply with the contents of this notice. The recipient further agrees to return to the Company, upon request, all documents and other material held by it relating to the project referred to in the Presentation. Persons falling within one of the categories of persons described above must comply with the terms of this disclaimer and they will conduct their own analyses or other verification of the data set out in this presentation and bear the responsibility for all or any costs incurred in doing so. Certain of the information contained in this Presentation has been obtained from published sources prepared by other parties. Certain other information has been extracted from unpublished sources prepared by other parties which have been made available to the Company. The information contained in the Presentation, which does not purport to be comprehensive, has been provided by the Company's management and has not been verified as to its accuracy, completeness or otherwise by the Company, by any of the Company's advisers or by any of their respective shareholders, directors, advisers, agents or affiliates. It may be subject to updating, completion, revision and/or amendment and such information may change materially at any time without further notice. SP Angel Corporate Finance LLP ("SP Angel"), CPS Capital Group Pty Ltd ("CPS Capital") and Shard Capital Partners LLP ("Shard Capital") are the appointed brokers to the Company and are acting in the provision of corporate finance business to the Company, within the meaning of the Financial Conduct Authority's Conduct of Business Sourcebook ("COBS"), and no-one else in connection with the matters contained in this Presentation. Accordingly, recipients should note that SP Angel, CPS Capital and Shard Capital are neither advising nor treating as a client any other person and will not be responsible to anyone other than the Company for providing the protections afforded to clients of it under the COBS nor for providing advice in relation to the matters contained in this Presentation. SP Angel, which is a member of the London Stock Exchange, is authorised and regulated in the United Kingdom by the Financial Conduct Authority (the "FCA") is acting as nominated adviser and joint broker to the Company in connection with Admission. For the avoidance of doubt, neither SP Angel, CPS Capital nor Shard Capital have authorised or approved the contents of the Presentation. The Company, SP Angel, CPS Capital and Shard Capital and their respective shareholders, directors, officers, agents, employees or advisers or any other person do not give, have not given, will not give and do not have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability, fairness, sufficiency or completeness of the information or opinions in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability is expressly disclaimed. Accordingly, the Company, SP Angel, CPS Capital and Shard Capital and their respective shareholders, directors, officers, agents, employees or advisers or any other person do not take any responsibility for, nor will they accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, save in the case of fraud, in respect of the accuracy, reliability, fairness, sufficiency or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements, negligent or otherwise, or for any direct, indirect or consequential loss or damage suffered by any person, howsoever arising, from the use of this Presentation. Each recipient must conduct its own independent investigation and analysis of the Company and of the information contained in this Presentation and obtain separate and independent verification of information and opinions contained in this Presentation as part of their own due diligence, and bear all the costs of doing so. This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. Forward-looking statements are identified by, amongst other things, the use of such terms as "anticipate", "assumes", "believe", "could", "envisage", "estimate", "expect", "forecast", "potential", "intend", "may", "plan", "should", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are statements, which are intended as a guide only, regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other important factors that relate to events and depend on circumstances that may or may not occur in the future and/or which are beyond the control of the Company (including, but not limited to, future market conditions, legislative and regulatory changes, the actions of governmental regulators, changes in the political, social, regulatory and/or economic framework in which the Company operates). These forward-looking statements are not guarantees of future performance of the Company and reflect assumptions and subjective judgements by the Company that are difficult to predict, qualify and/or quantify. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation. No representation or warranty is given as to the achievement or reasonableness of any projections, estimates, prospects or returns or any other forward-looking statements. No representation or warranty is made or assurance given that the statements, projections and forecasts contained in this Presentation will be borne out in practice or that the Company will perform as projected and the Company does not assume responsibility for verifying any of such statements, projections or forecasts. Neither the Company nor any persons shall be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on any statement in or omission from this Presentation. The Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or any additional information or to correct any inaccuracies in it, or omissions from it, which may become apparent. This Presentation is being delivered to interested parties for information only and upon the express understanding that such recipients will use it only for the purpose set out above. Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. The Company reserves the right without any notice or liability to the recipient of this Presentation or its advisers to: (i) change any of the procedures, timetable or requirements or terminate negotiations at any time prior to the signing of any binding agreement with investors; (ii) provide different information or access to information to different persons; (iii) agree variations to the property, rights and liabilities comprised in the Company; and (iv) negotiate at the same time with more than one person. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. This Presentation should not be considered a recommendation by the Company or any of its affiliates in relation to any prospective acquisition of shares in the Company. If you are in any doubt about the investment to which this Presentation relates, you should consult a person authorised by the FCA who specialises in advising on securities of the kind described in this Presentation.

# Why Coiled?



1

## Clinical Activity Before Targeted Exposure Levels Achieved

Clinical activity has emerged before targeted exposure levels and before maximum tolerated dose has been established. Cohort 4b demonstrated an 80% Clinical Benefit Rate versus 40% with once-daily dosing.

2

## Only Clinical-Stage TACC3 Inhibitor Globally

AO-252 is the only clinical-stage TACC3 inhibitor globally, targeting a biologically validated oncology pathway with no approved competitors. Independent DepMap analysis confirms TACC3 as a selective tumour dependency.

3

## Differentiated Pharmacology & Brain Penetration

AO-252 combines oral administration, blood-brain barrier penetration (most therapies cannot), direct cytotoxicity, and cGAS/STING immune activation in a single small molecule, supporting monotherapy and combination strategies.

4

## Proven Development Model & Shareholder Alignment

Leadership previously advanced the MLL-Menin programme into Biomea Fusion, which completed a Nasdaq IPO and later exceeded a \$1 billion market capitalisation. Management invested £1 million alongside institutional investors at AIM admission.

5

## Active Strategic Engagement

Multiple pharmaceutical organisations are engaged with the Company, including three under Confidentiality Agreement. These discussions have informed the design of the 2026 clinical programme and partnering data package.

6

## Catalyst-Rich 12-Month Outlook

Upcoming milestones include food effect PK data, next-generation formulation rollout, expansion cohorts, IO combination studies and development of a partner-relevant H2 2026 data package.

# AO-252 First –in–Class Oncology Asset with Emerging Clinical Activity and Multiple Near–Term Catalysts



Clinical activity, differentiated biology and a catalyst-rich development strategy support multiple pathways to value creation.

## ***Validated Target***

*Only clinical-stage TACC3 inhibitor with no direct competitors currently in the clinic*

## ***Emerging Clinical Activity***

*80% clinical benefit rate observed while dose optimisation remains ongoing*

## ***Expansion Cohorts Underway***

*Ovarian and prostate cancer cohorts designed to evaluate efficacy, biomarkers and commercial relevance*

## ***Active Pharmaceutical Engagement***

*Multiple pharma organisations engaged, including three under CDA, and all informing programme development*

# Phase 1 Trial: Evidence of Clinical Activity Before Maximum Exposure



Clinical benefit, durable responses and tumour reductions have emerged while dose optimisation remains ongoing.

## PHASE 1 (NCT06136884)



## SUPPORTING CLINICAL OBSERVATIONS

- BID dosing increased CBR from 40% to 80%
- Tumour reductions observed in ovarian and endometrial cancer
- Maximum tolerated dose not yet reached
- Clinical activity observed before targeted exposure levels achieved
- Clinical activity, durability and tumour reductions have emerged before targeted exposure levels have been achieved, supporting continued optimisation potential

# 2026 Clinical Expansion Strategy: Ovarian & Prostate Cancer



Expansion strategy guided by emerging clinical activity, biomarker rationale and strategic relevance.  
*Targeting ~40 Patients Across Ovarian and Prostate Expansion Cohorts by Q3 2026*

## Ovarian Cancer

*Efficacy demonstrated. Expansion programme underway.*

### Why it matters

- Significant unmet need following PARP resistance
- Limited treatment options in advanced disease
- Potential CNS opportunity

### Why AO-252 fits

- Distinct DNA damage repair mechanism
- Brain-penetrant small molecule
- Early clinical activity observed

## Prostate Cancer

*First patient enrolled. Biomarker enrichment hypothesis strongest.*

### Why it matters

- Resistance emerges following AR-targeted therapies
- Strong biomarker enrichment opportunity
- Significant unmet need in advanced disease

### Why AO-252 fits

- Independent of androgen receptor signalling
- Biomarker-driven approach targeting TP53/TACC3 biology
- Combination potential with IO and ADC therapies

Ovarian and prostate cancer offer the clearest path to demonstrating clinical relevance, biomarker utility and partnering potential.

## Why Pharma Cares

**PARTNER-RELEVANT CLINICAL DESIGN**  
2026 expansion cohorts designed to generate clinically meaningful and commercially relevant data.

**STRATEGIC ONCOLOGY CATEGORIES**  
Focused on tumour types with established partnering and acquisition activity.

**ACTIVE ENGAGEMENT**  
Multiple pharmaceutical organisations engaged, including three under Confidentiality Agreement

# Why AO-252 Matters Commercially



**350K+**

**Estimated Addressable Patients**

*Biomarker-defined populations across ovarian, prostate, TNBC, endometrial, gastric, and lung cancers in the US and Europe.*

**>\$20B**

**Established Commercial Oncology Markets**

*PARP, CDK4/6 and AR inhibitors demonstrate the commercial value of precision oncology and biomarker-driven treatment selection*

**>\$3B**

**Recent Strategic Transaction Benchmark**

*Johnson & Johnson's acquisition of Halda Therapeutics (November 2025) highlights continued pharmaceutical demand for differentiated Phase 1 oncology assets in advanced prostate cancer.*

## COMMERCIAL VALIDATION

- **DNA Damage Repair**

PARP inhibitors established the commercial importance of targeting DNA repair pathways.

- **Precision Oncology**

CDK4/6 inhibitors demonstrated how differentiated targeted therapies can evolve into multi-billion-dollar franchises.

- **Resistant Disease**

AR inhibitors validated large commercial opportunities in treatment-resistant patient populations.

# Value Creation Roadmap



## 2026-2027 CLINICAL MILESTONES

### Late Q2 2026

- Dose escalation completion
- Food effect PK data
- Recommended expansion strategy

### H2 2026 Clinical Dataset Build-Out

- New formulation rollout
- Enrolment acceleration
- Expansion cohorts initiated
- Target 20-30 patients treated

### H1 2027

- Key Value Inflection
- Preliminary efficacy dataset
- ~50-patient safety database
- Biomarker validation
- Prostate cancer cohort update
- Partnering data package

### H2 2027

- Strategic Execution
- Big Pharma partnering discussions
- Registrational pathway alignment
- RP2D confirmation
- Potential Phase 2 strategy

## PARTNERING STRATEGY

### Capital-Efficient Development

*Advance AO-252 through key clinical value inflection points while preserving capital and strategic flexibility.*

### Partner-Relevant Data Package

*Building the clinical dataset — efficacy, safety, biomarker — to support formal pharma BD discussions*

### Strategic Partnerships

*Pursue licensing, co-development and strategic investment opportunities to accelerate development and share risk.*

### Flexible Commercialisation

*Preserve optionality through independent development, regional licensing or broader strategic transactions.*

**Transaction Benchmark:** J&J's acquisition of Halda Therapeutics (November 2025, \$3.05B) confirms continued pharma demand for differentiated Phase 1 oncology assets in advanced prostate cancer.

# Recent Oncology Transactions



Recent oncology transactions demonstrate continued strategic demand for differentiated Phase 1 assets in commercially significant indications.

DATE	ACQUIRER	TARGET	UPFRONT PAYMENT	MILESTONES / CVRS	TOTAL POTENTIAL VALUE	PATIENT NUMBER	PHASE	INDICATIONS
Apr-26	Eli Lilly	Kelonia	\$3.25 Billion	\$3.75 Billion	\$7.0 Billion	4	(Platform play)	Leukemia
May-26	Merck	Terns Pharma	\$6.7Billion	-	\$5.8 Billion	85	Ph. 1/2	Chronic Leukemia
<b>Nov-25</b>	<b>J&amp;J</b>	<b>Halda</b>	<b>\$3.05 Billion</b>	<b>-</b>	<b>\$3.05 Billion</b>	<b>31</b>	<b>Ph. 1/2</b>	<b>Prostate and ER Breast</b>
Jan-25	Eli Lilly	Scorpion	\$1.5 Billion	\$1.0 Billion	\$2.5 Billion	40-50	Ph. 1	ER+ Breast
Jan-24	J&J	Ambrx	\$2.0 Billion	-	\$2.0 Billion	51	Ph. 1	Prostate
May-24	Genmab	Profound Bio	\$2.0 Billion	-	\$2.0 Billion	80	Ph. 1/2	Ovarian & Endometrium

Recent oncology transactions demonstrate that differentiated Phase 1 assets in large commercial indications continue to command multi-billion-dollar strategic valuations.

# AO-252 Investment Case

AO-252 combines early clinical activity, multiple near-term catalysts and strategic optionality within a first-in-class oncology programme.



1

## Clinical Validation Already Established

80% Clinical Benefit Rate in Cohort 4b, tumour reductions observed, no serious adverse events and MTD not yet reached.

2

## Five Catalysts Before YE 2026

Expansion cohorts, next-generation formulation, combination strategy initiation, partner-relevant data package and enrollment milestones.

3

## Partner-Relevant Development Strategy

Clinical expansion priorities have been designed to generate data relevant to future strategic discussions.

4

## Valuation Anchored to Transactions, Not Projections

Recent oncology transactions have demonstrated multi-billion-dollar valuations for differentiated Phase 1 assets in ovarian and prostate cancer. AO-252 is advancing within those same categories while maintaining a market capitalisation substantially below comparable transaction benchmarks.

# TACC3: An Untapped Oncology Target



TACC3 is overexpressed across multiple aggressive cancers and appears essential for tumour survival, while healthy adult tissue shows limited dependence.


**Pan-Cancer Relevance.** TACC3 is overexpressed across numerous commercially significant cancer types including ovarian, prostate, triple-negative breast, endometrial, gastric, bladder, sarcoma, lung, and brain metastases.

**Cancer Requires It. Adult Tissue Does Not.** Preclinical research suggests many cancer cells depend on TACC3 for survival, while healthy adult tissue demonstrates significantly lower dependence.

**Centrosome Amplification Driver.** TACC3 drives centrosome amplification, genomic instability and tumour progression—hallmarks of aggressive cancers. Once considered undruggable due to its protein structure, TACC3 is now targetable through Coiled's AO-252.

**Independent Validation.** Broad Institute DepMap analysis across thousands of cancer cell lines confirms TACC3 as a selective survival dependency in multiple tumour types. Similar approaches helped validate targets including BRCA, KRAS and MET before successful therapies emerged.

**Limited Competitive Landscape.** Despite growing scientific interest in TACC3, AO-252 is currently the only clinical-stage programme directly targeting the pathway.




# AO-252: How it Works & Why It Matters

Combines direct cancer-cell killing and immune activation in a single oral therapy.




- 1 Targeted DNA Damage Induction**  
AO-252 disrupts TACC3, causing DNA damage and replication stress in cancer cells
- 2 Innate Immune Activation (cGAS/STING)**  
Damaged DNA activates cGAS/STING, triggering an anti-tumour immune response
- 3 Direct Cancer Killing + Immune Activation**  
AO-252 attacks tumours through direct cancer-cell killing and immune activation



**AO-252 converts DNA damage into immune activation**

AO-252 combines two anti-tumour mechanisms in a single oral therapy, potentially broadening activity across multiple cancer types and treatment settings.

# AO-252: Multiple Sources of Clinical Differentiation



# Potential Clinical Opportunities for AO-252



CLINICAL PROBLEM	EXISTING THERAPIES	CURRENT TREATMENT GAPS	AO-252 ADVANTAGE
<p><b>Advanced Ovarian Cancer After PARP Resistance</b></p> <p>Most patients with advanced ovarian cancer eventually develop resistance to existing therapies, with limited treatment options remaining.</p>	<p>PARP inhibitors, Antibody drug conjugates</p>	<p>PARP resistance develops and brain metastases remain largely untreated.</p>	<p>Distinct mechanism beyond PARP inhibitors</p>
<p><b>Castration-Resistant Prostate Cancer</b></p> <p>Resistance to next-generation AR therapies continues to narrow treatment options in advanced prostate cancer.</p>	<p>Any indication after 1L of an anti-AR therapy, taxanes, radioligands</p>	<p>Resistance emerges following AR-targeted therapies and treatment options narrow significantly.</p>	<p>AR-independent mechanism with biomarker strategy</p>
<p><b>Solid Tumours with Brain Metastases</b></p> <p>Brain metastases remain difficult to treat because most targeted therapies fail to achieve meaningful CNS penetration.</p>	<p>ADCs, kinase inhibitors, biologics</p>	<p>Most targeted therapies fail to achieve meaningful CNS penetration.</p>	<p>Oral and brain-penetrant</p>
<p><b>Potential Combination Therapy Applications</b></p>	<p>Tubulin agents disruption potential</p>	<p>Toxicity and limited tolerability</p>	<p>Differentiated profile with combination potential</p>

# Pipeline



DISCOVERY

IND-ENABLING

PHASE 1

PHASE 2 & 3

## AO-252

TACC3 PPI Inhibitor  
First-in-Class Small  
Molecule

**Ovarian &  
Prostate Cancer**

*Phase 1 (Dose Expansion)*

*Primary focus — efficacy demonstrated; expansion targeting 40 patients by Q3 2026  
First patient enrolled November 2025; biomarker enrichment strategy active*

**Brain, Met**

*Enrollment Open*

**TNBC, Endo,  
Gastric, Pancreatic**

*Phase 1 (Active)*

*Active in dose escalation; expansion cohorts to be defined based on 2026 data*

## CO-001

STAT-6 siRNA  
Novel Immunology  
Modality

**Fibrosis, Asthma,  
Allergy**

*Discovery*

*IND submission assessment underway under new leadership*

*CO-001 (STAT-6 siRNA IND submission assessment underway under new leadership): Targets the same therapeutic pathway as Dupixent, which generated revenue exceeding £10 billion in 2024. The siRNA approach silences all STAT-6 isoforms at the mRNA level — mechanistically distinct from the degraders and inhibitors currently in clinical development.*

# Management & Board of Directors



## Dr Sotirios Stergiopoulos

### EXECUTIVE CHAIRMAN

- Physician executive with extensive pharmaceutical experience, particularly in Oncology
- Former CMO of multi-billion dollar Euronext-listed Ipsen
- Former Attending Physician and trainee at Albert Einstein College of Medicine, Harvard Medical School, and National Institutes of Health
- Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from Johns Hopkins University; Medical Degree from Poznan University of Medical Sciences (Poland)



## Sridhar Vempati

### CHIEF EXECUTIVE OFFICER

- ~20 years in drug discovery, oncology research & business strategy; proven track record advancing novel therapeutics from concept to clinical development
- Co-founded A2A Pharmaceuticals in 2016, previous business development roles at Ironwood Pharmaceuticals and Rafael Pharmaceuticals, and Equity Research analyst at Jefferies LLC
- Postdoctoral fellowship in leukaemia research at Dana Farber Cancer Institute (Harvard University), PhD in molecular biology from Ludwig-Maximilians-University, Germany, MBA from Boston University



## NON-EXECUTIVE DIRECTORS

### Jean Duvall (Independent NED)

- CEO & Director at Repronovo SA
- Former director, Exec VP & Group General Counsel at Ferring International Center

### Craig Tooman (Independent NED)

- President, Chief Executive Officer and Board Member and former CFO, Silence Therapeutics
- Former CuraVac, Vyome Therapeutics, Aratana Therapeutics

### Stephen West

- Fellow Chartered Accountant, 30+ years' international finance, corporate and public company experience
- Co-founder of EnergyPathways plc (AIM:EPP), Roquefort Therapeutics plc, TollCyto Therapeutics Ltd & ParisBio Ltd

### Dr Andrew Dean

- Head of Oncology, St John of God Subiaco Hospital, Western Australia; consults for GenesisCare
- Board member, Valo Therapeutics; research expertise in solid tumour molecular profiling and novel ovarian cancer therapies

# Capital Structure & Financials


AIM Admission **27 March 2026**

Placing Price **10 pence per share**

Gross Fundraise **£8.5 million (~\$11.3M USD)**

Market Cap **~£40 million (May 2026)**  
*Share price ~10p*

Total Shares Outstanding **425,856,539**





# Thank You

Coiled Therapeutics plc | [www.coiledplc.com](http://www.coiledplc.com) | [info@coiledplc.com](mailto:info@coiledplc.com)

*Harbor Access Investor Relations Contact Info to Come*

AIM: **COIL** | OTCQB: **COTXF**



**COILED**  
THERAPEUTICS



# Appendix

AIM: **COIL** | OTCQB: **COTXF**

# TACC3: A Validated Cancer Dependency



## WHAT IS TACC3?

TACC3 is a protein essential for cell division. Many cancers become highly dependent on TACC3 to sustain growth and survive genetic stress.

### Why is it important?

#### Why it matters

- Frequently overexpressed in aggressive cancers
- Linked to tumour progression and poorer outcomes
- Supports chromosome stability and cancer cell division
- Identified as a survival dependency across multiple tumour types

### Why is it considered validated?

TACC3 is considered a validated target because cancer cells depend on it for survival, and disrupting its function has been shown to impair tumour growth.

#### Why it matters

- Decades of research confirm TACC3's critical biological role
- Cancer studies consistently show elevated TACC3 in tumours
- Genetic and pharmacological inhibition reduces tumour growth in preclinical models
- Clinical datasets associate high TACC3 expression with worse patient outcomes

**Novel Drug Target.  
Proven Cancer Biology.**

**TACC3 has been extensively validated as a cancer dependency but has historically remained difficult to target therapeutically, creating a differentiated development opportunity.**


## WHY DOES IT MATTER NOW?

Historically considered difficult to target, advances in drug design are now enabling companies such as Coiled to pursue this well-validated cancer vulnerability.

# AO-252 Mechanism of Action Visual

## MULTI-TARGETED PPI DISRUPTION

By disrupting TACC3's protein-protein interactions, AO-252 induces mitotic & replication stress through impairment of the DNA damage repair process and activation of immunity, leading to cancer cell death, particularly in TP53-mutant cells, while showing minimal toxicity in healthy cells. AO-252 operates through a sophisticated mechanism that inhibits multiple critical protein-protein interactions at the TACC3 C-terminal domain. This disruption cascades across key proteins including DNA-PK, PARP1, BRCA, KU70, KIFC1, MBD2, and HDAC2 - collectively involved in mitosis, DNA damage repair, replication, and transcription.



### Biomarker Strategy

*Patient selection based on TP53 mutation status, high centrosomal amplification, and elevated TACC3 expression ensures precision targeting of responsive populations.*


# Robust Pre-Clinical Validation




AO-252 demonstrated **tumour regression as monotherapy** across multiple difficult-to-treat solid tumour models, including ovarian, triple-negative breast cancer (TNBC), endometrial, gastric, and prostate cancers. Notably, the compound showed robust efficacy in in vivo brain metastases models, addressing a critical unmet medical need.

**Tumour regression rates of 88-120%** were observed, with partial to complete responses consistently achieved across all tested indications. Additional strong activity was confirmed in NSCLC, SCLC, bladder, and esophageal cancer models.


## MDA-MB-231 (TNBC)




## HEC-59 (Endometrium)



## SKOV3 (Ovarian)



## VCAP (Prostate)



### Clean Safety Profile

- No toxicities observed in 28-day GLP studies (rats & dogs)
- Negative genetic toxicology across AMES and clastogenicity assays

### Selective Kinase Inhibition

- Only 4 of 468 kinases inhibited >65% at 1 $\mu$ M concentration
- Demonstrates exceptional target selectivity

### Strong Therapeutic Index

- Therapeutic window of  $\geq 3$ -5X maintained across all indications tested
- Supports favourable risk-benefit profile

# STAT-6 Programme — A Second Pipeline Opportunity

STAT-6 is the master transcription factor behind IL-4/IL-13 signalling — the same pathway Dupixent targets upstream to generate over £10 billion in 2024 revenue. CO-001 uses siRNA to silence STAT-6 at the mRNA level, a mechanistically distinct and potentially more complete approach than the degraders and inhibitors currently in clinical development.

## Current Landscape

Multiple STAT-6 degraders have entered the clinic with early efficacy signals, confirming target validity. CO-001 is differentiated: siRNA silencing operates upstream of protein production, avoiding the limitations of degradation-dependent or binding-dependent strategies.

## Reduced Risk

Partial target engagement (characteristic of degraders and inhibitors) can trigger compensatory isoform upregulation. Silencing at the mRNA level removes this escape mechanism, reducing the risk of resistance or attenuated response over time.

## Broader Silencing

mRNA-level silencing prevents all STAT-6 isoforms from forming including splice variants that degraders and inhibitors may leave active. This completeness of suppression is the core mechanistic advantage.

## Ind Assessment Underway

The new leadership team is conducting a formal assessment of the CO-001 programme for IND submission readiness and Phase 1 trial design. A go/no-go decision is expected within six to twelve months.

# Company History



2025

Coiled Therapeutics plc was spun out of A2A Pharmaceuticals in 2025 to advance AO-252, a first-in-class TACC3 inhibitor already in Phase 1 human trials.

2026

**March** – Completed a reverse takeover of AIM-listed Roquefort Therapeutics, raised £8.5 million at 10 pence per share from institutional and retail investors, and began trading on AIM under the ticker COIL on 27 March 2026.

**May** – The Company commenced cross-trading on the OTCQB Venture Market (COTXF), extending access to US-based investors.

This is not the first time this team has executed this model. In 2018, A2A Pharmaceuticals spun out its MLL-Menin inhibitor programme into Biomea Fusion. Biomea completed a Nasdaq IPO in 2021, raising \$153 million at a \$464 million listing market capitalisation — peaking above \$1 billion.

**The same founders. The same model.**  
*A clinical asset at a more advanced stage than any previous Coiled predecessor.*

## Company Facts

Exchange **AIM (London) + OTCQB (US)**

Tickers **COIL (AIM) | COTXF (OTCQB)**

AIM Admission **27 March 2026**

OTCQB Listing **19 May 2026**

Shares Outstanding **425,856,539**

Placing Price **10 pence per share**

Gross Proceeds **£8.5 million (~\$11.3M USD)**

Market Cap **~£40 million (May 2026)**

ISIN **GB00BSHRN331**

US IR: Harbor Access +1 475 477 9404